Skip to main content

Market Overview

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James

Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL)'s shares are not fully reflecting the company's growth potential and likely positive estimate revision bias, according to Raymond James. 

The Analyst

Raymond James analyst Nicholas Jansen upgraded shares of Quidel from Outperform to Strong Buy and increased the price target from $55 to $69.

The Thesis

After meetings with Quidel management at the 39th Annual Raymond James Institutional Investors Conference, Jansen said he identified the following as near-term catalysts and long-term opportunities. 

Near-Term Catalysts

  • Strong Q1 results: A better-than-thought Q1 flu season and strength in Sofia 2 and Solana placements are likely to help the company achieve revenue growth of 25 percent in Q1 compared to earlier expectations of 10-15 percent growth, the analyst said. Quidel's reference to its adjusted EBITA guidance as the "baseline" in the event of a normal flu season, suggesting likely upside, Jansen said.
  • Analyst day scheduled for April: Raymond James expects Quidel will provide a long-term product roadmap and go deeper into its growth drivers at the event, which could serve as a catalyst.

Long-Term Opportunities

  • The underappreciated installed base growth for the Sofia and Solana diagnostic testing platforms is becoming more valuable as the test menu expands
  • Raymond James said it has has increasing confidence in the Triage integration and additional revenue and cost synergy opportunities.
  • A long-term opportunity exists to cross-sell Quidel's product suite into new global commercial infrastructure, and the company has the potential for additional tuck-in M&A.

The Price Action

Quidel shares are up about 124 percent over the past year.

The stock was surging 4.59 percent to $49.03 at the time of publication Thursday afternoon. 

Related Links:

Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for QDEL

Mar 2021Craig-HallumMaintainsBuy
Mar 2021Raymond JamesMaintainsOutperform
Feb 2021Raymond JamesMaintainsOutperform

View More Analyst Ratings for QDEL
View the Latest Analyst Ratings


Related Articles (QDEL)

View Comments and Join the Discussion!

Posted-In: flu influenzaAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

AMWLKeybancInitiates Coverage On
OSPNSidoti & Co.Upgrades39.0
PLTSidoti & Co.Upgrades48.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at